GRI Bio (GRI) Competitors $1.30 -0.10 (-7.14%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. NERV, PHXM, HCWB, DWTX, LSB, APRE, PHIO, TLPH, CYCN, and ORGSShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Minerva Neurosciences (NERV), PHAXIAM Therapeutics (PHXM), HCW Biologics (HCWB), Dogwood Therapeutics (DWTX), Lakeshore Biopharma (LSB), Aprea Therapeutics (APRE), Phio Pharmaceuticals (PHIO), Talphera (TLPH), Cyclerion Therapeutics (CYCN), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors Minerva Neurosciences PHAXIAM Therapeutics HCW Biologics Dogwood Therapeutics Lakeshore Biopharma Aprea Therapeutics Phio Pharmaceuticals Talphera Cyclerion Therapeutics Orgenesis GRI Bio (NASDAQ:GRI) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Does the media prefer GRI or NERV? In the previous week, GRI Bio had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for GRI Bio and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.94 beat GRI Bio's score of 0.22 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment GRI Bio Neutral Minerva Neurosciences Positive Does the MarketBeat Community believe in GRI or NERV? Minerva Neurosciences received 341 more outperform votes than GRI Bio when rated by MarketBeat users. However, 85.71% of users gave GRI Bio an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformGRI BioOutperform Votes685.71% Underperform Votes114.29%Minerva NeurosciencesOutperform Votes34755.52% Underperform Votes27844.48% Which has more volatility & risk, GRI or NERV? GRI Bio has a beta of -1.68, suggesting that its share price is 268% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.37, suggesting that its share price is 137% less volatile than the S&P 500. Which has higher valuation and earnings, GRI or NERV? GRI Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGRI BioN/AN/A-$13.04M-$11.56-0.11Minerva NeurosciencesN/AN/A-$30M$0.822.23 Is GRI or NERV more profitable? Minerva Neurosciences' return on equity of 0.00% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets GRI BioN/A -289.05% -165.01% Minerva Neurosciences N/A N/A -6.74% Do analysts prefer GRI or NERV? GRI Bio currently has a consensus price target of $22.00, indicating a potential upside of 1,592.31%. Minerva Neurosciences has a consensus price target of $5.00, indicating a potential upside of 173.97%. Given GRI Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe GRI Bio is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in GRI or NERV? 34.0% of GRI Bio shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 0.1% of GRI Bio shares are held by insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryMinerva Neurosciences beats GRI Bio on 8 of the 15 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.78M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.118.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book0.256.536.974.60Net Income-$13.04M$143.48M$3.23B$248.06M7 Day Performance-5.80%0.20%-0.88%-1.02%1 Month Performance-12.75%10.93%7.81%3.51%1 Year Performance-97.73%2.46%31.53%12.68% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.0219 of 5 stars$1.30-7.1%$22.00+1,592.3%-97.5%$2.78MN/A-0.111News CoverageAnalyst ForecastShort Interest ↑Analyst RevisionNERVMinerva Neurosciences3.4135 of 5 stars$1.56+1.3%$5.00+220.5%-45.1%$10.91MN/A-3.559Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageHCWBHCW Biologics3.4341 of 5 stars$7.21-6.7%$35.00+385.4%-87.5%$10.38M$1.45M-7.2140Short Interest ↓Gap DownDWTXDogwood Therapeutics2.0114 of 5 stars$5.27+1.7%$10.00+89.8%N/A$10.07MN/A-0.805LSBLakeshore Biopharma0.6345 of 5 stars$1.07flatN/AN/A$9.96M$672.27M0.00773APREAprea Therapeutics3.2385 of 5 stars$1.80+3.4%$15.50+761.1%-54.8%$9.96M$580K-0.647Positive NewsShort Interest ↑High Trading VolumePHIOPhio Pharmaceuticals3.7541 of 5 stars$2.05+2.5%$4.00+95.1%-61.8%$9.84MN/A-0.1910Short Interest ↓Gap DownTLPHTalphera2.447 of 5 stars$0.48-2.6%$5.00+945.8%-48.3%$9.80M$27K-0.6919CYCNCyclerion Therapeutics1.8793 of 5 stars$2.96+5.3%N/A+36.6%$9.50M$2.08M-2.5530ORGSOrgenesis1.5526 of 5 stars$1.95+0.4%N/AN/A$9.35M$662K0.00150Gap Up Related Companies and Tools Related Companies NERV Alternatives PHXM Alternatives HCWB Alternatives DWTX Alternatives LSB Alternatives APRE Alternatives PHIO Alternatives TLPH Alternatives CYCN Alternatives ORGS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRI Stock Free GRI Stock Alerts